公司資料
Aprea Therapeutics 股價、新聞與催化劑
- 股票代碼:
- APRE
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.69 USD (+1.49%)
收盤價
最後更新: 2026年8月17日
9.46M USD
市值
股價為何變動
As of Aug 17, 2026, APRE closed up 1.49% at $0.6900. No new same-company headline was identified in the current news window.
公司概覽
DNA Damage Response Oncology
Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells.
APR-1051
APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for advanced solid tumors. The program is designed to improve the therapeutic window relative to earlier WEE1 inhibitors.
Biomarker-Directed Expansion
Aprea is expanding APR-1051 in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. It also plans combination work in HPV-positive head-and-neck cancer and colorectal cancer.
ATRN-119
ATRN-119 is a macrocyclic ATR inhibitor that has completed Phase 1 dose escalation. Aprea is evaluating potential combination development with immunotherapy, chemotherapy, antibody-drug conjugates, and radiation.
未來催化劑
- Clinical data update from the Phase 1 ACESOT-1051 study of APR-1051 at a medical meeting in the fourth quarter of 2026.
- Potential entry of Aprea's macrocyclic DYRK1A/B inhibitor into IND-enabling studies in the fourth quarter of 2026.
- Completion of APR-1051 dose escalation and backfill expansion in the second quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。